{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PS-341+%28Velcade-drug%29", "query": { "intervention": "PS-341 (Velcade-drug)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 108, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PS-341+%28Velcade-drug%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-03T09:45:37.461Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05556616", "title": "A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Modakafusp alfa", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-12", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 14, "location_summary": "Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05556616" }, { "nct_id": "NCT00425503", "title": "PS-341 Followed by Removal of Prostate for Those With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "PS-341 (bortezomib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2001-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00425503" }, { "nct_id": "NCT01497275", "title": "Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle-Cell Lymphoma" ], "interventions": [ { "name": "Rituximab, Bortezomib,Y90 ibritumomab tiuxetan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2012-02", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-07-15", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01497275" }, { "nct_id": "NCT01428492", "title": "Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "GSK2110183", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2011-12", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2018-08-08", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01428492" }, { "nct_id": "NCT03909464", "title": "Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Malignancy", "Malignant Neoplasm", "Neuropathy", "Neuropathies Sensory", "Chemotherapy-induced Peripheral Neuropathy" ], "interventions": [ { "name": "Neurosensory testing with Pressure-Specified Sensory Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2017-11-29", "completion_date": "2019-11-25", "has_results": false, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03909464" }, { "nct_id": "NCT06152575", "title": "MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 492, "start_date": "2024-02-08", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 100, "location_summary": "Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06152575" }, { "nct_id": "NCT00111748", "title": "UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade, Thalidomide, Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2005-02", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111748" }, { "nct_id": "NCT06158841", "title": "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 421, "start_date": "2024-05-19", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06158841" }, { "nct_id": "NCT06577025", "title": "A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2024-08-20", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 5, "location_summary": "Duarte, California • San Francisco, California • Iowa City, Iowa + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06577025" }, { "nct_id": "NCT06208150", "title": "A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Talquetamab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 838, "start_date": "2024-01-22", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-03T09:45:37.461Z", "location_count": 49, "location_summary": "Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208150" } ] }